Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse PersonsColleen F. Kelley, Renu Singh, Maribel Acevedo-Quiñones et al.|New England Journal of Medicine|2024Cited by 260
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trialOnyema Ogbuagu, Hui Wang, Nicolas Margot et al.|The Lancet HIV|2023Cited by 71
Strategies for implementing long‐acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI studyKatherine Nelson, Nanlesta Pilgrim, Alftan Dyson et al.|Journal of the International AIDS Society|2025Cited by 4